Literature DB >> 29544612

The Taiwan Heart Registries: Its Influence on Cardiovascular Patient Care.

Cho-Kai Wu1, Jyh-Ming Jimmy Juang1, Jiun-Yang Chiang1, Yi-Heng Li2, Chia-Ti Tsai3, Fu-Tien Chiang4.   

Abstract

Taiwanese heart registries for the main cardiovascular diseases have been conducted in the past 10 years, with the goal of examining the quality of cardiovascular patient care, which cannot be guaranteed by the universal Taiwan National Health Insurance. The results show suboptimal adherence to guideline recommendations. Door-to-balloon time and dual antiplatelet therapy use in acute coronary syndrome, standard medications for management of heart failure, low-density lipoprotein cholesterol levels in dyslipidemia, anticoagulant agent use in atrial fibrillation, and the understanding of sudden arrhythmia death syndrome were all found to be inadequate. However, all were improved, either by changing National Health Insurance policy or through continuous education for physicians and patients. Thus, specific cardiovascular disease registries could help examine the status of real-world practice, find inadequacies in guideline implementation and understanding of rare diseases, facilitate lobbying to policy makers and education for physicians and patients, and influence and improve cardiovascular patient care.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary; dyslipidemia; failure; fibrillation; insurance; sudden death

Mesh:

Year:  2018        PMID: 29544612     DOI: 10.1016/j.jacc.2018.02.006

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Clinical significance of quantitative assessment of right ventricular glucose metabolism in patients with heart failure with reduced ejection fraction.

Authors:  Szu-Ying Tsai; Yen-Wen Wu; Shan-Ying Wang; Yu-Chien Shiau; Kuan-Ming Chiu; Hao-Yuan Tsai; Chien-Lin Lee; Jung-Cheng Hsu; Chung-Ming Tu; Heng-Hsu Lin; Shan-Hui Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

2.  Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy.

Authors:  Ming-Yun Ho; Po-Wei Chen; Wen-Han Feng; Chun-Hung Su; Sheng-Wei Huang; Chung-Wei Cheng; Hung-I Yeh; Ching-Pei Chen; Wei-Chun Huang; Ching-Chang Fang; Hui-Wen Lin; Sheng-Hsiang Lin; I-Chang Hsieh; Yi-Heng Li
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

Review 3.  Management of acute coronary syndrome in patients with suspected or confirmed coronavirus disease 2019: Consensus from Taiwan Society of Cardiology.

Authors:  Yi-Heng Li; Mei-Tzu Wang; Wei-Chun Huang; Juey-Jen Hwang
Journal:  J Formos Med Assoc       Date:  2020-07-13       Impact factor: 3.282

4.  Genome-Wide Copy Number Variation Association Study of Atrial Fibrillation Related Thromboembolic Stroke.

Authors:  Chia-Shan Hsieh; Pang-Shuo Huang; Sheng-Nan Chang; Cho-Kai Wu; Juey-Jen Hwang; Eric Y Chuang; Chia-Ti Tsai
Journal:  J Clin Med       Date:  2019-03-09       Impact factor: 4.241

5.  Impact of multi-disciplinary treatment strategy on systolic heart failure outcome.

Authors:  Shyh-Ming Chen; Yen-Nan Fang; Lin-Yi Wang; Ming-Kung Wu; Po-Jui Wu; Tsung-Hsun Yang; Yung-Lung Chen; Chi-Ling Hang
Journal:  BMC Cardiovasc Disord       Date:  2019-10-15       Impact factor: 2.298

6.  GSTM3 variant is a novel genetic modifier in Brugada syndrome, a disease with risk of sudden cardiac death.

Authors:  Jyh-Ming Jimmy Juang; Anna Binda; Shyh-Jye Lee; Juey-Jen Hwang; Wen-Jone Chen; Yen-Bin Liu; Lian-Yu Lin; Chih-Chieh Yu; Li-Ting Ho; Hui-Chun Huang; Ching-Yu Julius Chen; Tzu-Pin Lu; Liang-Chuan Lai; Shih-Fan Sherri Yeh; Ling-Ping Lai; Eric Y Chuang; Ilaria Rivolta; Charles Antzelevitch
Journal:  EBioMedicine       Date:  2020-07-07       Impact factor: 8.143

7.  Renal protective effect of sacubitril/valsartan in patients with heart failure.

Authors:  Chun-You Chen; Cheng-Hsien Chen; Po-Hsun Huang; Chung-Te Liu; Hui-Ling Hsieh; Shih-Chang Hsu; Wen-Cheng Huang; Yuh-Mou Sue; Feng-Yen Lin; Chun-Ming Shih; Yue-Cune Chang
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

8.  Profiles of Hospitalized Patients with Angiographic Coronary Heart Disease in Taiwan during 2014-2016: Report of a Tertiary Hospital.

Authors:  Wen-Yu Lin; Yuan Hung; Gen-Min Lin; Chin-Sheng Lin; Jun-Ting Liou; Cheng-Chung Cheng; Tsung-Neng Tsai; Wei-Che Tsai; Tzu-Chiao Lin; Wen-Cheng Liu; Pang-Yen Liu; Keng-Yi Wu; Chih-Hsueng Hsu; Fang-Han Yu; Shu-Meng Cheng; Shih-Ping Yang; Wei-Shiang Lin; Chun-Hsien Wu
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

9.  Feature and impact of guideline-directed medication prescriptions for heart failure with reduced ejection fraction accompanied by chronic kidney disease.

Authors:  Yung-Lung Chen; Chi-Ling Hang; Chien-Hao Su; Po-Jui Wu; Huang-Chung Chen; Hsiu-Yu Fang; Yen-Nan Fang; Cheng-I Cheng; Morgan Fu; Shyh-Ming Chen
Journal:  Int J Med Sci       Date:  2021-04-28       Impact factor: 3.738

10.  The impact of door-to-electrocardiogram time on door-to-balloon time after achieving the guideline-recommended target rate.

Authors:  Chih-Kuo Lee; Shih-Wei Meng; Ming-Hsien Lee; Hsiu-Chi Chen; Chia-Ling Wang; Hui-Ning Wang; Min-Tsun Liao; Mu-Yang Hsieh; Yung-Chung Huang; Edward Pei-Chuan Huang; Chih-Cheng Wu
Journal:  PLoS One       Date:  2019-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.